-
公开(公告)号：DK2313111T3
公开(公告)日：2013-12-02
申请号：DK09803657
申请日：2009-07-31
Applicant: VENTIRX PHARMACEUTICALS INC
Inventor： HOWBERT JEFFRY J , DIETSCH GREG , HERSHBERG ROB , DUVVURI MURALIKRISHNA
IPC: A61K9/08 , A61K9/00 , A61K9/19 , A61K31/395 , A61K31/724 , A61K47/00 , A61K47/48 , A61P31/12 , A61P35/00
-
公开(公告)号：WO2010014913A8
公开(公告)日：2010-04-01
申请号：PCT/US2009052422
申请日：2009-07-31
Applicant: VENTIRX PHARMACEUTICALS INC , HOWBERT J JEFFRY , DUVVURI MURALIKRISHNA , HERSHBERG ROB , DIETSCH GREG
Inventor： HOWBERT J JEFFRY , DUVVURI MURALIKRISHNA , HERSHBERG ROB , DIETSCH GREG
IPC: A61K39/395
CPC classification number: A61K31/55 , A61K9/0019 , A61K9/08 , A61K9/19 , A61K31/724 , A61K47/40 , A61K47/48969 , A61K47/6951 , B82Y5/00 , C07D223/16 , C08B37/0012
Abstract: The present invention is directed generally to stable formulations of a TLR agonist preferably a TLR7 or a TLR8 agonist, for use in the treatment of cancer, preferably solid tumors and lymphomas. Specifically, the present invention is directed to stable formulations of up to 50 mg/ml of a TLR agonist which comprise a cyclodextrin.
Abstract translation: 本发明一般涉及用于治疗癌症，优选实体瘤和淋巴瘤的TLR激动剂，优选TLR7或TLR8激动剂的稳定制剂。 具体地，本发明涉及高达50mg / ml的包含环糊精的TLR激动剂的稳定制剂。
-
公开(公告)号：PT2313111E
公开(公告)日：2013-12-05
申请号：PT09803657
申请日：2009-07-31
Applicant: VENTIRX PHARMACEUTICALS INC
Inventor： HOWBERT JEFFRY J , DUVVURI MURALIKRISHNA , HERSHBERG ROB , DIETSCH GREG
IPC: A61K9/08 , A61K9/00 , A61K9/19 , A61K31/395 , A61K31/724 , A61K47/00 , A61K47/48 , A61P31/12 , A61P35/00
-
公开(公告)号：AU2016203386B2
公开(公告)日：2017-07-06
申请号：AU2016203386
申请日：2016-05-24
Applicant: VENTIRX PHARMACEUTICALS INC
Inventor： HOWBERT J JEFFRY , DUVVURI MURALIKRISHNA , HERSHBERG ROB , DIETSCH GREG
IPC: A61K39/395
Abstract: The present invention is directed generally to stable formulations of a TLR agonist preferably a TLR7 or a TLR8 agonist, for use in the treatment of cancer, preferably solid tumors and lymphomas. Specifically, the present invention is directed to stable formulations of up to 50 mg/ml of a TLR agonist which comprise a cyclodextrin.
-
公开(公告)号：AU2009276403B2
公开(公告)日：2016-03-10
申请号：AU2009276403
申请日：2009-07-31
Applicant: VENTIRX PHARMACEUTICALS INC
Inventor： HOWBERT J JEFFRY , DUVVURI MURALIKRISHNA , HERSHBERG ROB , DIETSCH GREG
IPC: A61K39/395
Abstract: The present invention is directed generally to stable formulations of a TLR agonist preferably a TLR7 or a TLR8 agonist, for use in the treatment of cancer, preferably solid tumors and lymphomas. Specifically, the present invention is directed to stable formulations of up to 50 mg/ml of a TLR agonist which comprise a cyclodextrin.
-
Patent Agency Ranking
公开(公告)号：CA2732437A1
公开(公告)日：2010-02-04
申请号：CA2732437
申请日：2009-07-31
Applicant: VENTIRX PHARMACEUTICALS INC
Inventor： HOWBERT J JEFFRY , DUVVURI MURALIKRISHNA , HERSHBERG ROB , DIETSCH GREG
Abstract: The present invention is directed generally to stable formulations of a TLR agonist preferably a TLR7 or a TLR8 agonist, for use in the treatment of cancer, preferably solid tumors and lymphomas. Specifically, the present invention is directed to stable formulations of up to 50 mg/ml of a TLR agonist which comprise a cyclodextrin.
-
公开(公告)号：AU2009276403A1
公开(公告)日：2010-02-04
申请号：AU2009276403
申请日：2009-07-31
Applicant: VENTIRX PHARMACEUTICALS INC
Inventor： HOWBERT J JEFFRY , DUVVURI MURALIKRISHNA , HERSHBERG ROB , DIETSCH GREG
IPC: A61K39/395
Abstract: The present invention is directed generally to stable formulations of a TLR agonist preferably a TLR7 or a TLR8 agonist, for use in the treatment of cancer, preferably solid tumors and lymphomas. Specifically, the present invention is directed to stable formulations of up to 50 mg/ml of a TLR agonist which comprise a cyclodextrin.
-
公开(公告)号：CA2732437C
公开(公告)日：2017-11-21
申请号：CA2732437
申请日：2009-07-31
Applicant: VENTIRX PHARMACEUTICALS INC
Inventor： HOWBERT J JEFFRY , DUVVURI MURALIKRISHNA , HERSHBERG ROB , DIETSCH GREG
Abstract: The present invention is directed generally to stable formulations of a TLR agonist preferably a TLR7 or a TLR8 agonist, for use in the treatment of cancer, preferably solid tumors and lymphomas. Specifically, the present invention is directed to stable formulations of up to 50 mg/ml of a TLR agonist which comprise a cyclodextrin.
-
公开(公告)号：AU2016203386A1
公开(公告)日：2016-06-16
申请号：AU2016203386
申请日：2016-05-24
Applicant: VENTIRX PHARMACEUTICALS INC
Inventor： HOWBERT J JEFFRY , DUVVURI MURALIKRISHNA , HERSHBERG ROB , DIETSCH GREG
IPC: A61K39/395
Abstract: The present invention is directed generally to stable formulations of a TLR agonist preferably a TLR7 or a TLR8 agonist, for use in the treatment of cancer, preferably solid tumors and lymphomas. Specifically, the present invention is directed to stable formulations of up to 50 mg/ml of a TLR agonist which comprise a cyclodextrin.
-
公开(公告)号：PL2313111T3
公开(公告)日：2014-08-29
申请号：PL09803657
申请日：2009-07-31
Applicant: VENTIRX PHARMACEUTICALS INC
Inventor： HOWBERT J JEFFRY , DUVVURI MURALIKRISHNA , HERSHBERG ROB , DIETSCH GREG
IPC: A61K9/08 , A61K9/00 , A61K9/19 , A61K31/395 , A61K31/724 , A61K47/00 , A61K47/48 , A61P31/12 , A61P35/00
-
-
-
-
-
-
-
-
-
Search Results
12
records
(took 0.02 seconds)
